The various consultation exercises have resulted in a variety of “what we heard” reports and documents provided. The Patented Medicine Prices Review Board, for example, in its guidelines, has provided revised guidelines. There have been multiple-step consultations. Health Canada will be posting, in the coming weeks, a report on its consultations regarding the strategy for rare disease drugs. There is a great deal of transparency in terms of the engagement.
On June 18th, 2021. See this statement in context.